Document Detail


Genetic removal of basal nitric oxide enhances contractile activity in isolated murine collecting lymphatic vessels.
MedLine Citation:
PMID:  23420659     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The role of nitric oxide (NO) in regulating lymphatic contractile function and, consequently, lymph flow has been the subject of intense study. Despite this, the precise effects of NO on lymphatic contractile activity remain unclear. Recent hypotheses posit that basal levels of endogenous NO increase lymphatic contraction strength as a consequence of lowering frequency (i.e. positive lusitropy), whereas higher agonist-evoked concentrations of NO exert purely inhibitory effects on contractile function. We tested both hypotheses directly by isolating and cannulating collecting lymphatic vessels from genetically modified mice for ex vivo study. The effects of basal NO and agonist-evoked NO were evaluated, respectively, by exposing wild-type (WT), endothelial NO synthase (eNOS)(-/-) and inducible NO synthase (iNOS)(-/-) lymphatic vessels to controlled pressure steps followed by ACh doses. To compare with pharmacological inhibition of eNOS, we repeated both tests in the presence of l-NAME. Surprisingly, genetic removal of basal NO enhanced contraction amplitude significantly without increasing contraction frequency. Higher levels of NO production stimulated by ACh evoked dilation, decreased tone, slowed contraction frequency and reduced fractional pump flow. We conclude that basal NO specifically depresses contraction amplitude, and that greater NO production then inhibits all other aspects of contractile function. Further, this work demonstrates definitively that mouse collecting lymphatic vessels exhibit autonomous, large-amplitude contractions that respond to pressure similarly to collecting lymphatics of other mammalian species. At least in the peripheral lymphatic vasculature, NO production depresses contractile function, which influences lymph flow needed for fluid regulation, humoral immunity and cancer metastasis.
Authors:
Joshua P Scallan; Michael J Davis
Related Documents :
23382329 - Exploring the link between cardiovascular reactivity and end-organ damage in african an...
23308239 - Pre-weaning growth hormone treatment reverses hypertension and endothelial dysfunction ...
3606259 - Left ventricular preparation with an extrathoracically adjustable balloon occluder.
20116869 - Cardiovascular changes after transcatheter endovascular stenting of adult aortic coarct...
10978259 - Reduction of aortic wall motion inhibits hypertension-mediated experimental atheroscler...
3229019 - Intravenous labetalol for the control of hypertension following repair of coarctation o...
6084769 - Direct effects of streptokinase on the isolated rat myocardium.
3763079 - Influence of crystalloid versus colloid infusion on peripartum colloid osmotic pressure...
9008249 - A randomized study comparing a patient-directed hypertension management strategy with u...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2013-02-18
Journal Detail:
Title:  The Journal of physiology     Volume:  591     ISSN:  1469-7793     ISO Abbreviation:  J. Physiol. (Lond.)     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-04-16     Completed Date:  2013-10-18     Revised Date:  2014-04-15    
Medline Journal Info:
Nlm Unique ID:  0266262     Medline TA:  J Physiol     Country:  England    
Other Details:
Languages:  eng     Pagination:  2139-56     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Enzyme Inhibitors / pharmacology
Lymphatic Vessels / physiology*
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
NG-Nitroarginine Methyl Ester / pharmacology
Nitric Oxide / physiology*
Nitric Oxide Synthase Type II / deficiency,  genetics
Nitric Oxide Synthase Type III / antagonists & inhibitors,  deficiency,  genetics
Grant Support
ID/Acronym/Agency:
HL-089784/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Enzyme Inhibitors; 31C4KY9ESH/Nitric Oxide; EC 1.14.13.39/Nitric Oxide Synthase Type II; EC 1.14.13.39/Nitric Oxide Synthase Type III; EC 1.14.13.39/Nos2 protein, mouse; EC 1.14.13.39/Nos3 protein, mouse; V55S2QJN2X/NG-Nitroarginine Methyl Ester
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intrauterine inflammation alters cardiopulmonary and cerebral haemodynamics at birth in preterm lamb...
Next Document:  Regulation of connexin36 gap junction channels by n-alkanols and arachidonic acid.